| Document |
Document Title |
|
WO/2023/116811A1 |
A short peptide compound containing β-aminoketone and the use thereof, and specifically disclosed is a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/116587A1 |
A binuclear platinum complex luminescent material having the structure of chemical formula (I), applied to an organic light-emitting diode and having good luminous efficiency and long device life. Also provided is an organic electrolumin...
|
|
WO/2023/118373A1 |
The present inventors have shown that specific benzene sulfonamide thiazole compounds (I) have the ability to induce an early endoplasmic reticulum stress. These compounds also lead to cancerous cells growth inhibition and death.
|
|
WO/2023/115394A1 |
A diarylamine compound and use thereof, a light extraction material, an electroluminescent device, and a display device. The structural general formula of the diarylamine compound is formula (I).
|
|
WO/2023/120452A1 |
This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by fo...
|
|
WO/2023/122472A1 |
Provided are aqueous pharmaceutical formulations comprising 4-((2-hydroxy-3-methoxybenzyl)amino)-benzenesulfonamide 12-LOX inhibitors with improved solubility. Also provides are aqueous parenteral pharmaceutical formulations comprising s...
|
|
WO/2023/114977A1 |
Described herein are compounds useful as S1PR4 receptor antagonists, pharmaceutical compositions comprising said compounds, methods of making said compounds and pharmaceutical compositions, and methods of using said compounds and pharmac...
|
|
WO/2023/111996A1 |
Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating cancers can include administering an effective amount of at least one ...
|
|
WO/2023/114822A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/112722A1 |
The present invention addresses the problem of providing: a compound suitably used for forming an optical anisotropic membrane that has excellent reverse wavelength dispersion property and moist heat durability; a polymerizable compositi...
|
|
WO/2023/104182A1 |
A compound for preventing or treating a tumor overexpressing YY1 and the use thereof. The anti-tumor drug can effectively bind to YY1, triggers the degradation of YY1 by means of a ubiquitin-proteasome pathway, and releases the inhibitor...
|
|
WO/2023/106625A1 |
The present invention relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
|
|
WO/2023/102140A1 |
The disclosure provides compounds and their use in treating medical diseases or disorders, such as coronavirus infection. Pharmaceutical compositions and methods of making various compounds are provided. The compounds are contemplated to...
|
|
WO/2023/098612A1 |
A salt form and a crystal form of a dimethyl sulfoximine derivative, and a preparation method therefor. Specifically disclosed are a hydrate, a salt form and crystal form of a compound of formula (I), and a method for preparing the compo...
|
|
WO/2023/102162A1 |
Described herein are novel compounds, compositions and methods for treatment of diseases including cancer using such compounds, compositions, and methods. The compounds include those of Formula (I):
|
|
WO/2023/101595A1 |
The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and bin...
|
|
WO/2023/098613A1 |
Disclosed in the present invention is a method for preparing a dimethyl sulfinyl imine derivative and an intermediate thereof, and specifically disclosed is a method for preparing a compound of formula (I) and an intermediate thereof.
|
|
WO/2023/094830A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R1, R2, R3 and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion ch...
|
|
WO/2023/096258A1 |
The present invention relates to a pharmaceutical composition and a health functional food composition for preventing or treating inflammatory bowel disease, comprising riluzole and a novel riluzole derivative as an active ingredient. Ri...
|
|
WO/2023/092175A1 |
The invention relates generally to a compound of Formula (I), wherein R1 is a bicyclic fused heterocyclic moiety and R2 is H or F. The compound of Formula (I) or a pharmaceutically acceptable salt thereof has potential medical use in the...
|
|
WO/2023/078271A1 |
Disclosed are an aromatic compound, a preparation method therefor, an intermediate thereof, a pharmaceutical composition thereof, and a use thereof, specifically relating to an aromatic compound shown in formula I, a tautomer, stereoisom...
|
|
WO/2023/077726A1 |
The present invention provides an organic compound, a light extraction layer material, and an organic electronic device. The structure of the organic compound is represented as general formula (1). The organic compound can be used as the...
|
|
WO/2023/077218A1 |
There is provided a process for alkylating a substrate with a photocatalytic system. The process comprises providing a mixture containing an acid, and a substrate (an organic compound). Then, an organophotoredox catalyst of formula Ia is...
|
|
WO/2023/073634A1 |
Compounds containing the carbamoselenoyl and/or sulfamoyl function, usable as selective antifungal agents against Malassezia pachydermatis strains for topical veterinary and human use, having the following general structures: Formula I; ...
|
|
WO/2023/076626A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/076615A1 |
The present disclosure relates to methods for treating chronic rhinosinusitis with a composition comprising an effective amount of a N-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamide DPP1 inhibitor compound of Formula (I) or a pharma...
|
|
WO/2023/074936A1 |
The present disclosure relates to a bifunctional compound using a UBR box domain-binding ligand. The UBR box domain is a domain commonly present in the UBR (Ubiquitin protein ligase E3 component n-recognin) protein of the N-end rule path...
|
|
WO/2023/071073A1 |
The present application discloses an arylamine organic compound and the use thereof. The arylamine organic compound has a structure as shown in general formula (1). The arylamine organic compound has a relatively high glass transition te...
|
|
WO/2023/066359A1 |
It provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. It also provides methods for treating LPA-associated diseases, disorders, and conditions.
|
|
WO/2023/060866A1 |
The present invention belongs to the field of heterocyclic compounds, and specifically relates to a process for synthesizing accelerator CBS by air oxidation of MBTS, which comprises the following steps: (1) uniformly mixing MBTS, cycloh...
|
|
WO/2023/062627A1 |
Provided herein are compounds that inhibit the protein-protein interaction of serine acetyltransferase (SAT) with O-acetyl serine sulfhydrylase (OASS), and can therefore be used as herbicides.
|
|
WO/2023/063112A1 |
The present disclosure provides an organic compound represented by general formula [1]. In formula [1], R1 and R2 are each independently selected from a hydrogen atom, an alkyl group, or the like. R3 are each independently selected from ...
|
|
WO/2023/061051A1 |
Disclosed in the present application are a class of compounds containing a thiazole or thiadiazole structure and the use thereof, which belong to the technical field of medicine. According to the present application, the structure of a l...
|
|
WO/2023/058046A1 |
The present invention relates to the process for the preparation of Nitazoxanide and intermediates thereof. The invention explores readily available starting materials with reaction conditions that are suitable for industrial scale appli...
|
|
WO/2023/056740A1 |
The present invention belongs to the field of heterocyclic compounds, and in particular relates to a production process for a rubber vulcanization accelerator MBTS. The process comprises the following steps: (1) mixing MBT and a solvent ...
|
|
WO/2023/056739A1 |
The present invention belongs to the field of heterocyclic compounds, and specifically relates to a production process for accelerator DCBS. The production process comprises the following steps: 1) mixing MBTS and a mixed solvent under a...
|
|
WO/2023/056447A1 |
Disclosed herein are compounds that can be used to selectively detect nitric oxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting nitric oxide using the compounds.
|
|
WO/2023/047855A1 |
The present invention provides: a photosensitive composition which is not susceptible to an excessive decrease in the weight of components in the photosensitive composition or composition (in cases where the photosensitive composition or...
|
|
WO/2023/044315A2 |
The present disclosure relates to compounds of Formula I and II and pharmaceutically acceptable salts thereof: and a pharmaceutical composition including a compound of formula I or II and a pharmaceutically acceptable excipient. Also pro...
|
|
WO/2023/040106A1 |
Disclosed in the present invention is a preparation method for an acetamide compound by means of green visible-light catalysis. In the method, LED lamps are used as light sources to provide energy, and economically available aromatic ami...
|
|
WO/2023/043208A1 |
The objective of the present invention is to provide a novel derivative that exhibits an anticancer activity through eIF2α phosphorylation efficacy through the strategy of substituting a urea core with a 2-aminobenzothiazole core in whi...
|
|
WO/2023/044046A1 |
The present application relates novel bifunctional compounds, which function to recruit BCL-XL protein to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof. In particular, the present disclosure provides bi...
|
|
WO/2023/039170A1 |
The present invention relates compounds having the general structure of formulas I and II, and other compounds having similar activity, including any pharmaceutically acceptable salts thereof. The invention includes the use of such compo...
|
|
WO/2023/009712A9 |
The present disclosure provides heteroaryloxy thiazolo azine compounds and compositions thereof useful for inhibiting JAK2.
|
|
WO/2023/031200A1 |
The present invention relates to malonamide compounds of the formula (I) where the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of the s...
|
|
WO/2023/023853A1 |
This invention provides compound having a structure of Formula (I)or (II): (I, II ) and uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are a...
|
|
WO/2023/020534A1 |
Provided herein are compounds of Formula I, II, and III, which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds; pharmaceutical compositions comprising the compounds; as ...
|
|
WO/2023/019665A1 |
A multifunctional rubber vulcanization additive, and a preparation method therefor and the use thereof. The multifunctional rubber vulcanization additive is at least one represented by structural formula (I), wherein R1 is selected from ...
|
|
WO/2023/022896A1 |
The present disclosure encompasses Ponesimod crystalline forms, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2023/018747A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) used to treat a condition or disease that is associated with hypoxia, or with increased expression of hypoxia-inducible factor HI...
|
